TAGS ™

Extending Health with
Early PAD Screening

First of Its Kind

Point of Care Early Detection System for PAD

Detects natural release of hydrogen sulfide gas
Compares gas levels released from lower and upper limbs
Provides a quick, snapshot of vascular health in the office

Dec 8, 2020

US PATENT NO: US 10,856,790 B2

Transdermal sampling strip and method for analyzing transdermal emitted gases.

>> View Patent
Jan 2023

European Patent No: EP 3 242 596 B1

Method for analyzing trandermally emitted gases

>> View Patent
Aug 2024

US PATENT NO: US 12,053,281 B2

Transdermal sampling strip and method for analyzing transdermal emitted gases.

>> View Patent

Diabetic foot complications lead to second highest 5-year mortality rates

Problem: Needing Early Detection of PAD

Diabetes is a growing health crisis

Peripheral Artery Disease (PAD), caused by diabetes, reduces lower leg circulation

Wounds, created by PAD, that don’t heal leading to

Lower limb amputations
Microvascular disease comorbidities

Costing $21 billion annually

Diabetic foot complications lead to second highest 5-year mortality rates

Problem: Needing Early Detection of PAD

Diabetes is a growing health crisis

Peripheral Artery Disease (PAD), caused by diabetes, reduces lower leg circulation

Wounds, created by PAD, that don’t heal leading to

Lower limb amputations
Microvascular disease comorbidities

Costing $21 billion annually

Solution:

TAGS (Transdermal Arterial Gasotransmitter Sensor)

Identifies: Decreased lower limb circulation (PAD) by sensing in healthy H₂S gas emissions

Predicts: Coronary artery disease or Chronic Limb Threatening Ischemia (CLTI)

Prevents: Heart attack and stroke, and diabetic amputations with early medical intervention

Better + Cheaper + Faster + Preventative

How is TAGS better than current PAD diagnostic devices?

The patented TAGS system is the first of its kind, early detection device for PAD and the only diagnostic device suitable for POC use. TAGS is better, cheaper and faster than current noninvasive PAD diagnostic devices, and the only device targeted for patient screening and monitoring.

Although TAGS is a more comfortable, accurate and easy-to-use diagnostic tool for PAD, it would not replace angiography, duplex ultrasonography, T_CPO₂ or ABI in every case, but it would fill a critical gap upstream: enabling early, scalable, routine detection of PAD before patients reach advanced stages requiring expensive, invasive interventions.